FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growthInterim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024Conference call to be held today at 8:30 am EDTLOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 3 ...

Company to Host Conference Call and Webcast on August 7, 2024LOS ANGELES, July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates.Conferenc ...

LOS ANGELES, May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Wednesday, June 5, 2024, from 2:00 PM – 2:25 PM EDT.The fireside chat will be webcast live on ...

Core Insights - Aadi Bioscience, Inc. announced new nonclinical data showing that nab-sirolimus has significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets, and greater antitumor activity compared to intravenous and oral mTOR inhibitors in a xenograft model [1][2] - The findings support further clinical exploration of nab-sirolimus as a single agent or in combination with other therapies [1][2] Group 1: Nonclinical Data Findings - Nab-sirolimus demonstrated significantly greater suppression of tumor growth in A549 xenografts compared to IV temsirolimus and oral sirolimus and everolimus [2] - Average intratumoral drug concentrations 24 hours after IV mTOR inhibitor treatment were 420-539 ng/g for nab-sirolimus, compared to 34.9 ng/g for temsirolimus and 13.2 ng/g for its active metabolite [2] - Tumor uptake of nab-sirolimus greatly exceeded that of sirolimus and everolimus at steady-state [2] Group 2: Clinical Trials and Future Directions - Aadi will present a trials-in-progress poster on its Phase 2 trial in advanced or recurrent endometrioid-type endometrial cancer (EEC), which is a difficult-to-treat mTOR-driven cancer [3] - The Phase 2 study aims to evaluate the efficacy and safety of nab-sirolimus in combination with letrozole for patients with advanced or recurrent EEC [3][4] - Dysregulation of mTOR signaling is implicated in over 80% of EEC cases, which harbor PTEN or PI3K/AKT/mTOR pathway alterations [3] Group 3: Company Overview - Aadi Bioscience focuses on developing and commercializing therapies for cancers with alterations in the mTOR pathway [5] - The company combines nanoparticle albumin-bound (nab) technology with sirolimus to enhance drug delivery, stability, solubility, and targeting [2][5] - Aadi has received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa) [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-385 ...

Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Dave Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Tara Bancroft - TD Cowen Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscien ...

PRESS RELEASE Exhibit 99.1 Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES, CA, May 8, 2024 – Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-sta ...

Company to Host Conference Call and Webcast on May 8, 2024LOS ANGELES, May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates.Conference Call Inf ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aadi Bioscience, Inc. (AADI) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aadi Bioscience, Inc. is one of 1054 individual stocks in the Medical sector. Collectively, the ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aadi Bioscience, Inc. (AADI) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aadi Bioscience, Inc. is one of 1064 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 differen ...